Proton Beam Primer from IBA
Particle Therapy: An established treatment option now within reach
Particle Therapy is recognized as having the most favorable dose deposition properties possible with external beam techniques. The results obtained in research and clinical applications of Particle Therapy on more than 50,000 patients over the past decades, have clearly established its efficacy in the treatment of cancer.
With 20 years of experience in the industry, and having built and operated hundreds of cyclotrons, we've developed record-setting project teams backed by the highest-quality manufacturing processes and a well-established supply chain. IBA offers flexible equipment configurations, project scopes up to and including turnkey facilities, full non-clinical operational models including all system maintenance -- backed by educated and accessible sources of financing -- IBA is best-positioned to place this capability within reach for you.
Only 5% of 130,000 U.S. patients have access to Particle Therapy now while Europe and Asia face an even greater underserved demand !
Today, cancer is the second highest cause of death in developed countries. Its treatment still presents a real challenge. At IBA, we see each day as a fresh challenge in the ongoing battle to find ways of fighting this disease.
About 45% of all patients can now be cured through the use of surgery, radiation therapy and/or chemotherapy. About 50% of all patients receive radiation therapy during the course of their treatment. Most radiation therapy is delivered with beams external to the body, of which Particle Therapy is the most precise.
Of the 130,000 new patients eligible to undergo Particle Therapy in the U.S every year, only 5% of them will actually benefit from this great technology.
As anyone familiar with external beam radiotherapy knows, an unfortunate consequence is the unavoidable “spilling” of radiation into tissues proximal, distal, and adjacent to the tumor.
The ever-expanding list of indications suitable for Particle Therapy, given its greater precision control over dose deposition and potential to complement and enhance other forms of therapy, is causing more healthcare providers to seek out this treatment option for their patients and community. Read more here.
Particle Therapy is recognized as having the most favorable dose deposition properties possible with external beam techniques. The results obtained in research and clinical applications of Particle Therapy on more than 50,000 patients over the past decades, have clearly established its efficacy in the treatment of cancer.
With 20 years of experience in the industry, and having built and operated hundreds of cyclotrons, we've developed record-setting project teams backed by the highest-quality manufacturing processes and a well-established supply chain. IBA offers flexible equipment configurations, project scopes up to and including turnkey facilities, full non-clinical operational models including all system maintenance -- backed by educated and accessible sources of financing -- IBA is best-positioned to place this capability within reach for you.
Only 5% of 130,000 U.S. patients have access to Particle Therapy now while Europe and Asia face an even greater underserved demand !
Today, cancer is the second highest cause of death in developed countries. Its treatment still presents a real challenge. At IBA, we see each day as a fresh challenge in the ongoing battle to find ways of fighting this disease.
About 45% of all patients can now be cured through the use of surgery, radiation therapy and/or chemotherapy. About 50% of all patients receive radiation therapy during the course of their treatment. Most radiation therapy is delivered with beams external to the body, of which Particle Therapy is the most precise.
Of the 130,000 new patients eligible to undergo Particle Therapy in the U.S every year, only 5% of them will actually benefit from this great technology.
As anyone familiar with external beam radiotherapy knows, an unfortunate consequence is the unavoidable “spilling” of radiation into tissues proximal, distal, and adjacent to the tumor.
The ever-expanding list of indications suitable for Particle Therapy, given its greater precision control over dose deposition and potential to complement and enhance other forms of therapy, is causing more healthcare providers to seek out this treatment option for their patients and community. Read more here.
